HAIC has been combined with sorafenib to leverage the synergistic effects of the combination.
HAIC已与索拉非尼联合使用，以利用该联合使用的协同效应。
A randomized Phase 2 trial was conducted to compare HAIC plus sorafenib with sorafenib alone as a first-line therapy for patients with CP score of up to B7; the trial demonstrated that HAIC plus sorafenib resulted in a higher ORR (21.7% vs.7.3%) and longer OS (median survival, 10.6 vs. 8.6 months, p = 0.031) [44].
一项随机II期试验比较了HAIC加索拉非尼与单独索拉非尼作为CP评分高达B7的患者的一线治疗方法；该试验表明，HAIC+索拉非尼可导致更高的ORR(21.7% vs.3%)，OS更长(中位生存期，10.6 vs.8.6个月，p=0.031) [44].
Subsequently, Kudo et al.[45] conducted the SILIUS trial, a multicenter randomized Phase 3 trial comparing frontline use of sorafenib with or without HAIC, and confirmed a higher ORR and longer time to progression (TTP) in the combination group, but the OS were similar between two groups.
随后，Kudo等人，[45]进行了SILIUS试验，这是一项多中心随机3期试验，比较索拉非尼的一线使用，证实联合组有更高的ORR和更长的进展时间(TTP)，但两组之间的OS相似。
They also conducted a subgroup analysis and revealed the combination therapy yielded longer OS than sorafenib treatment did in patients with Vp4 PVT.
他们还进行了亚组分析，发现门静脉瘤栓Vp4患者的联合治疗比单独索拉非尼治疗产生了更长的OS。
He et al. [47] reported another randomized Phase 3 trial comparing sorafenib with or without HAIC in 2019 in patients with PVT (Vp4: 37%); the results showed that patients treated with the combination therapy exhibited more favorable outcomes, including higher ORRs and longer OS periods (median survival, 13..4 vs. 7.1 months; HR 0.35; p < 0.01).
何等人[47]在2019年报道了另一项随机III期临床试验，比较索拉非尼联合或不联合HAIC治疗门静脉瘤栓患者(Vp4：37%)；结果显示，接受联合治疗的患者表现出更有利的结果，包括更高的ORR和更长的OS期(中位生存期，13.4 vs.7.1个月；HR 0.35; p < 0.01).
.
Although these two studies have reported opposite results regarding the effects of first-line HAIC combination, they differed in several aspects.
虽然这两项研究对一线HAIC联合治疗的效果报道了相反的结果，但它们在几个方面有所不同。
First, they enrolled different patients: all patients enrolled in the study by He et al. had PVT, whereas only 63.2% of those in the study by Kudo et al. had PVT.
首先，他们招募的患者不同：He等人研究的患者都有PVT，而Kudo等人的研究中只有63.2患者PVT。
Hepatitis B virus–related HCC was less prevalent in the study by Kudo et al. (23.4%) than in the study by He et al. (80%).
在Kudo等人的研究中，乙型肝炎病毒相关的HCC的发病率较低(23..4%，而He等人的研究为80%.。
Second, He et al.administered an oxaliplatin-based regimen, modified FOLFOX6, every 3 weeks, which is also a common intravenous chemotherapy regimen for advanced HCC in China; by contrast, the regimen in the SILIUS trial was cisplatin plus 5-fluorouracil (5-FU) every 4 weeks.
第二，He等人，以奥沙利铂为基础的方案，改良FOLFOX6，这也是中国晚期HCC常见的静脉化疗方案；相比之下，SILIUS试验中的方案为每4周顺铂+5-氟尿嘧啶（5-FU）。
Because of inherent differences between oxaliplatin and cisplatin, the use of these two platinum-based chemotherapeutic modalities may result in different synergistic effects with sorafenib [58].
由于奥沙利铂和顺铂之间的内在差异，使用这两种铂类化疗方式可能会导致与索拉非尼[58]产生不同的协同效应。
Third, He et al. used repeated intra-arterial catheterization, which allows for the adjustment of the microcatheter tip position and the re-embolization of newly developed gastroduodenal collateral arteries.
第三，He等人，采用重复的动脉内置管，可调整微导管尖端位置，重新栓塞新发展的胃十二指肠侧支动脉。
These differences may contribute to the different OS results in these two trials.
这些差异可能导致了这两个试验中不同的OS结果。
In summary, HAIC combined with sorafenib could provide favorable ORR and may provide OS benefits.
总之，HAIC联合索拉非尼可以提供良好的ORR，并可能提供OS效益。
Further research should be conducted to explore the optimal chemotherapeutic agents, protocol procedures, and target patient populations.
进一步的研究需要探索最佳的化疗药物、方案程序和目标患者群体。
Data regarding the combination of HAIC with lenvatinib are limited.
关于HAIC与来伐替尼联合使用的数据有限。
A retrospective study of 24 patients treated with HAIC plus standard-dose lenvatinib reported an encouraging ORR of 58% and a disease control rate of 79% [48].
一项对24例接受HAIC+标准剂量来伐替尼治疗的患者的回顾性研究，报告了令人鼓舞的ORR为58%，疾病控制率为79%[48]。
Additional prospective studies of the combination of HAIC and lenvatinib are ongoing.
关于HAIC和来伐替尼联合使用的其他前瞻性研究正在进行中。
|